


# Maximizing treatment benefit for patients with ALK-positive NSCLC

13.10–14.20, Friday 28 March 2014

Room C, Palexpo

Geneva, Switzerland



## Dear Colleagues

On behalf of the faculty, I am pleased to welcome you to the Pfizer Oncology satellite symposium: '**Maximizing treatment benefit for patients with ALK-positive NSCLC**'.

Our understanding of tumour biology is advancing rapidly, and consequently we are now able to target numerous identifiable molecular alterations with specific therapies. With the identification of epidermal growth factor receptor mutations and anaplastic lymphoma kinase (ALK) translocations as oncogenic drivers, the treatment of non-small cell lung cancer (NSCLC) has particularly benefited from this progress.

ALK-positive NSCLC was only identified as a distinct molecular entity in lung cancer in 2007, nevertheless crizotinib was approved in Europe in 2012 for adult patients with pretreated ALK-positive NSCLC.

In this symposium, we will be discussing the treatment management of patients with ALK-positive NSCLC based on a review of the crizotinib clinical trials as well as respective personal experience from the faculty members; discussion points will include ALK testing, management of adverse events, duration of treatment, as well as intracranial activity of crizotinib.

I hope you enjoy what I'm sure will be an interesting and informative symposium.

**Federico Cappuzzo, Chair**  
Istituto Toscano Tumori, Livorno, Italy

## Programme

- 13.10 **Welcome**  
Federico Cappuzzo, Chair (Italy)
- 13.15 **Crizotinib clinical data in second-line, ALK-positive NSCLC**  
Alice Shaw (USA)
- 13.35 **Panel discussion: Management of treatment with crizotinib**  
All faculty
- 13.55 **Building on clinical trial evidence: Real-life crizotinib case studies**  
Sanjay Popat (UK)
- 14.10 **Panel discussion: Activity in the brain and management of challenging clinical situations**  
All faculty; close of the meeting by Federico Cappuzzo, Chair (Italy)